1. Home
  2. ACCS vs INMB Comparison

ACCS vs INMB Comparison

Compare ACCS & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ACCS

ACCESS Newswire Inc.

BUY

Current Price

$7.08

Market Cap

38.0M

ML Signal

BUY

Logo INmune Bio Inc.

INMB

INmune Bio Inc.

HOLD

Current Price

$1.44

Market Cap

40.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACCS
INMB
Founded
1988
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Publishing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.0M
40.1M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
ACCS
INMB
Price
$7.08
$1.44
Analyst Decision
Strong Buy
Hold
Analyst Count
1
3
Target Price
$14.00
$4.30
AVG Volume (30 Days)
19.6K
332.6K
Earning Date
03-24-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$22,646,000.00
$50,000.00
Revenue This Year
$0.18
$264.29
Revenue Next Year
$7.16
N/A
P/E Ratio
N/A
N/A
Revenue Growth
42.30
19.05
52 Week Low
$6.86
$1.38
52 Week High
$13.35
$11.64

Technical Indicators

Market Signals
Indicator
ACCS
INMB
Relative Strength Index (RSI) 25.85 41.81
Support Level $6.86 $1.44
Resistance Level $7.61 $1.67
Average True Range (ATR) 0.37 0.12
MACD -0.20 -0.01
Stochastic Oscillator 6.84 12.82

Price Performance

Historical Comparison
ACCS
INMB

About ACCS ACCESS Newswire Inc.

ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.

About INMB INmune Bio Inc.

INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.

Share on Social Networks: